Page 3 - Replimune Group News Today

Caption Management LLC purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,968 shares of the company’s stock, valued at approximately $766,000. Caption Management LLC owned approximately 0.06% […]

Key Insights Using the 2 Stage Free Cash Flow to Equity, Replimune Group fair value estimate is US$9.64 Replimune Group...

-- Health care stocks were slipping late Tuesday afternoon with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund off 0.1%. The iShares Biotechnology ETF dropped...

Mirae Asset Global Investments Co. Ltd. boosted its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,226 shares of the company’s stock after purchasing an additional 1,649 shares […]

Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove or reduce cancerous lesions in a midstage study.

Massachusetts Biotech Plummets as Skin Cancer Trial Fails

(Reuters) - Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove ...

Replimune Group's experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron's Libtayo, failed to significantly re

Said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a mid-stage study. The therapy, RP1, in combination…

Replimune Group Inc. shares dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet...